Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing Brand Resources

Full Prescribing Info

Indications/Uses

Renal Cell Carcinoma (RCC): CABOMETYX is indicated as monotherapy for advanced renal cell carcinoma: as first line treatment of adult patients with intermediate or poor risk (see Pharmacology: Pharmacodynamics under Actions); in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy (see Pharmacology: Pharmacodynamics under Actions).
CABOMETYX, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults (see Pharmacology: Pharmacodynamics under Actions).
Hepatocellular Carcinoma (HCC): CABOMETYX is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.

Cabometyx Indications/Uses

cabozantinib

Manufacturer:

Ipsen Pharma

Distributor:

Zuellig Pharma